½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting






»¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

021-54845833/15800441009

Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > Íÿ¹INAVA¶à¿Ë¡¿¹Ìå

²úÆ·ÖÐÐÄ

×îвúÆ·

  • Íÿ¹INAVA¶à¿Ë¡¿¹Ìå

    ¹æ¸ñ£º
    ¼Û¸ñ£º£¤
    • Æ·ÅÆ : ͨεÉúÎï
    • Ŀ¼ºÅ : TW9589
    • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
    • »õÆÚ : ÏÖ»õ
    • ¹æ¸ñ £º100ul/200ul/25ul
  • ÉÌÆ·ÏêÇé
  • ²Î¿¼ÎÄÏ×
  • ˵Ã÷ÊéÏÂÔØ
  • ÉÌÆ·ÆÀÂÛ0
  • Ïà¹Ø²úÆ·

ÖÐÎÄÃû³Æ£º Íÿ¹INAVA¶à¿Ë¡¿¹Ìå

Ó¢ÎÄÃû³Æ£º Anti-INAVA rabbit polyclonal antibody

±ð    Ãû£º innate immunity activator; C1orf106

Ïà¹ØÀà±ð£º Ò»¿¹

´¢    ´æ£º Àä¶³£¨-20¡æ£©

ËÞ    Ö÷£º Rabbit

¿¹    Ô­£º INAVA

·´Ó¦ÖÖÊô£º Human, Mouse

±ê ¼Ç Î Unconjugate

¿Ë¡ÀàÐÍ£º rabbit polyclonal

¼¼Êõ¹æ¸ñ

Background:

Expressed in peripheral macrophages and intestinal myeloid-derived cells, is required for optimal PRR (pattern recognition receptor)-induced signaling, cytokine secretion, and bacterial clearance. Upon stimulation of a broad range of PRRs (pattern recognition receptor) such as NOD2 or TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9, associates with YWHAQ/14-3-3T, which in turn leads to the recruitment and activation of MAP kinases and NF-kappa-B signaling complexes that amplifies PRR-induced downstream signals and cytokine secretion (PubMed:28436939). In the intestine, regulates adherens junction stability by regulating the degradation of CYTH1 and CYTH2, probably acting as substrate cofactor for SCF E3 ubiquitin-protein ligase complexes. Stabilizes adherens junctions by limiting CYTH1-dependent ARF6 activation (PubMed:29420262).

Applications:

ELISA, IHC

Name of antibody:

INAVA

Immunogen:

Fusion protein of human INAVA

Full name:

innate immunity activator

Synonyms:

C1orf106

SwissProt:

Q3KP66

IHC positive control:

Human liver cancer

IHC Recommend dilution:

50-300






¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿